prof. dr. F.P.J.G. (Floris) Lafeber
Full Professor
- Rheumatology & Clinical Immunology
Contact
Biography
Floris Lafeber (1961) is professor of ‘Experimental Rheumatology’ at the UMC Utrecht. He studied Biology at the University of Nijmegen (NL; graduated Nov 1984) and did his PhD at this University in collaboration with the Univerity of Leiden (NL), with a visit of three months at the department of Physiology, Univ. of Ottawa (Canada) (graduated April 1988). He is scientifically active in the field of ‘Regenerative Medicine’ and ‘Immunology’.
Currently, his main research interest is in 1) Implementation of joint distraction in the treatment of knee osteoarthritis; 2) The potential of IL4-10 synerkine in control of cartilage damage, inflammation, and pain in osteoarthritis (and haemophilic arthropathy); 3) The prediction of progression and response to treatment in osteoarthritis, rheumatoid arthritis, and haemophilic arthropathy.
Floris Lafeber is (co-)author of over 300 peer-reviewed papers (H-index 48), of which more than half in the top 10% of the field. He co-supervised 30 PhD students with several additionally scheduled. He has several patent (provisional) in the fields described above, and gained over his career for more than 15 million Euros research funding from the Dutch Arthritis Association, government, and industry. At present he is manager of research and head of research laboratory of the department of Rheumatology & Clinical Immunology, UMCU (3 days/week)
Side Activities
Manager Research of the Division of Internal Medicine & Dermatology (2018 - present) 1 day/week
Director (CSO), co-founder, and shareholder of ArthroSave BV (2016 - present) 2 days / week
Member of the steering committee of APPROACH within IMI (2015-2021)
Member of: OsteoArthritis Research Society International (OARSI); Orthopaedic Research Society (ORS); and International Cartilage Repair Society (ICRS) (present)
Member of the Advisory Board Biobanking (2019-present)
Consultant: SynerkinePharma BV
Reviewer for several international journals and funding agencies
Research Output (389)
Sialic Acid-Engineered IL4-10 Fusion Protein is Bioactive and Rapidly Cleared from the Circulation
Steen-Louws Cristine, Boross Peter, Prado Judith, Meeldijk Jan, Langenhorst Jurgen B, Huitema Alwin D R, den Hartog Marcel T, Boon Louis, Lafeber Floris P J G, Hack C Erik, Eijkelkamp Niels, Popov-Celeketic Jelena dec 2019, In: Pharmaceutical Research. 37
Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis:an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials
Verhoeven Maxime M.A., De Hair Marjolein J.H., Tekstra Janneke, Bijlsma Johannes W.J., Van Laar Jacob M., Pethoe-Schramm Attila, Borm Michelle E.A., Ter Borg Evert Jan, Linn-Rasker Suzanne P., Teitsma Xavier M., Lafeber Floris P.J.G., Jacobs Johannes W.G., Welsing Paco M.J. 1 okt 2019, In: Annals of the Rheumatic Diseases. 78 , p. 1333-1338 6 p.
Effectiveness of Remission Induction Strategies for Early Rheumatoid Arthritis:a Systematic Literature Review
Verhoeven M. M.A., Welsing P. M.J., Bijlsma J. W.J., van Laar J. M., Lafeber F. P.J.G., Tekstra J., Jacobs J. W.G. 23 apr 2019, In: Current Rheumatology Reports. 21
Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment:Study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis
Besselink N. J., Westgeest A. A.A., Klaasen R., Gamala M., Van Woerkom J. M., Tekstra J., Verhoeven M. M.A., Van Spil W. E., Lafeber F. P.J.G., Marijnissen A. C.A., Van Laar J. M., Jacobs J. W.G. 17 apr 2019, In: Trials. 20
Is prediction of clinical response to methotrexate in individual rheumatoid arthritis patients possible? A systematic literature review
Roodenrijs Nadia M.T., van der Goes Marlies C., Welsing Paco M.J., Tekstra Janneke, van Laar Jacob M., Lafeber Floris P.J.G., Bijlsma Johannes W.J., Jacobs Johannes W.G. 11 apr 2019, In: Joint Bone Spine. 87 , p. 13-23 11 p.
Can optical spectral transmission assess ultrasound-detected synovitis in hand osteoarthritis?
Besselink N. J., Jacobs J. W.G., Westgeest A. A.A., Van Der Meijde P., Welsing P. M.J., Marijnissen A. C.A., Lafeber F. P.J.G., Van Spil W. E. 1 feb 2019, In: PLoS ONE. 14
Canine IL4-10 fusion protein provides disease modifying activity in a canine model of OA; An exploratory study
Van Helvoort E. M., Popov-Celeketic J., Eijkelkamp N., Coeleveld K., Tryfonidou M. A., Wijne C. D., Hack C. E., Lafeber F. P.J.G., Mastbergen S. C. 1 jan 2019, In: PLoS ONE. 14 18 p.
The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients:a post hoc analysis of three cohort studies
Roodenrijs Nadia M.T., de Hair Maria J.H., Wheater Gill, Elshahaly Mohsen, Tekstra Janneke, Teng Y. K.Onno, Lafeber Floris P.J.G., Hwang Ching Chang, Liu Xinyu, Sasso Eric H., van Laar Jacob M. 20 nov 2018, In: Arthritis research & therapy. 20 1 p.
Models of arthropathy:what can we learn from them to improve patient care?
Pulles Astrid E, Lafeber Floris P J G, van Vulpen Lize F D 19 sep 2018, In: Rheumatology (Oxford, England). 58 , p. 565-566 2 p.
Gewrichtsschade ten gevolge van hemofilie
van Vulpen LFD, Pulles AE, Lafeber FPJG, Mastbergen SC, Schutgens REG sep 2018, In: Nederlands Tijdschrift voor Hematologie. 15 , p. 257 264 p.